Neuronetics Beats Q4 Targets as Integrated Health Model Shows Promise

MALVERN, Pa. – March 03, 2026 – As Neuronetics, Inc. (NASDAQ: STIM) prepares to host its fourth-quarter 2025 earnings call on March 17, the company has already signaled a significant financial and strategic turning point. Preliminary results released in February show the medical technology firm not only surpassed analyst revenue expectations but also achieved positive operating cash flow, offering the first concrete validation of its transformative shift into a vertically integrated healthcare provider.

The announcement comes just over a year after Neuronetics completed its acquisition of Greenbrook TMS, a network of mental health treatment centers. The move was a high-stakes pivot from a purely device-focused business to one that both manufactures its flagship NeuroStar Advanced Therapy system and operates the clinics that deliver the treatment. Now, with strong performance driven by its new clinic segment, the company is providing an early glimpse of a strategy that appears to be paying off.

A Financial Turnaround Fueled by a New Strategy

Neuronetics reported preliminary unaudited revenue of $41.8 million for the fourth quarter of 2025, comfortably exceeding the analyst consensus of $40.66 million. This figure represents a staggering 86% year-over-year increase on an as-reported basis. More importantly, when viewed on an adjusted pro forma basis to account for the Greenbrook acquisition, revenue still grew by a robust 23%.

A closer look at the revenue breakdown reveals the engine of this growth. The newly formed Clinic segment, representing the legacy Greenbrook operations, generated $23.5 million, a 37% increase on an adjusted pro forma basis. In contrast, the traditional NeuroStar device sales segment posted $18.3 million, a more modest but still healthy 9% pro forma increase, with 49 systems shipped during the quarter.

Perhaps the most significant milestone in the preliminary report was the achievement of $0.9 million in positive operating cash flow for the quarter. This marks a critical inflection point for the company, fulfilling a key promise made to investors following the Greenbrook merger and signaling a sustainable path toward profitability. For the full year 2025, preliminary revenue reached $149.2 million, landing squarely within the company's revised guidance and demonstrating a 99% as-reported increase over 2024.

The Greenbrook Gamble Appears to Be Paying Off

The strong financial results are a direct reflection of Neuronetics' bold vertical integration strategy. The December 2024 acquisition of Greenbrook TMS was designed to create a powerful synergy between device manufacturing and service delivery. By controlling both the technology and the point of care, Neuronetics aimed to increase brand awareness, standardize treatment protocols, and capture more of the value chain.

The company has been aggressively optimizing its new assets. Following the merger, Neuronetics undertook a strategic restructuring, gaining court approval to close 23 underperforming Greenbrook centers to focus on its most profitable locations. This move was part of a broader plan to realize at least $15 million in annualized cost synergies and streamline operations for maximum efficiency.

The strategy is now expanding beyond its owned-and-operated centers. In October 2025, Neuronetics announced an exclusive three-year partnership with Elite DNA Behavioral Health, a large mental health provider with over 30 locations. Under the agreement, Neuronetics will serve as the sole provider of TMS devices and will leverage its Greenbrook operational platform to offer support services. This partnership model represents a scalable new channel for growth, allowing Neuronetics to extend its integrated service expertise to independent practices and further entrench its NeuroStar systems in the market.

Navigating a Crowded and Evolving Market

While Neuronetics celebrates its internal successes, the external landscape for neurostimulation is becoming increasingly competitive. The global market for Transcranial Magnetic Stimulation (TMS) systems, valued at over $1.4 billion in 2025, is projected to nearly double by the early 2030s, attracting intense innovation and competition.

Throughout 2025, key rivals made significant strides. BrainsWay received FDA clearance for an accelerated, six-day Deep TMS protocol for Major Depressive Disorder (MDD) and expanded its label to include adolescent MDD. Similarly, MagVenture and Magstim also secured FDA clearances for treating adolescent MDD, a key growth demographic for which Neuronetics had previously gained an indication. These moves have leveled the playing field and intensified the race to capture market share.

Furthermore, the very definition of neurohealth treatment is expanding. In a potentially disruptive development, the FDA approved Flow Neuroscience's headset in December 2025, the first prescription-based brain stimulation device designed for at-home use in treating MDD. While it uses a different technology (tDCS), its launch in Q2 2026 represents a new paradigm of accessibility that could challenge the in-clinic model that Neuronetics and its direct competitors rely on.

Despite the competition, broad market trends remain favorable. The regulatory environment is becoming more accommodating, with insurers like Cigna's Evernorth eliminating prior authorization requirements for TMS in early 2026, and TRICARE expanding coverage to include adolescents. This wider acceptance and improved reimbursement landscape provides a tailwind for the entire industry.

Leadership and the Road Ahead

As Neuronetics solidifies its new integrated identity, it is also preparing for a change in leadership. President and CEO Keith Sullivan has announced his plan to retire effective June 30, 2026, after guiding the company through its strategic transformation. The board has initiated a search for his successor, and Sullivan will remain as a consultant to ensure a smooth transition.

Investors and analysts will be watching the upcoming March 17 conference call with keen interest. Beyond the final audited numbers, they will be listening for management's official guidance for 2026, updates on the CEO search, and further details on how the company plans to sustain its growth momentum. Key questions will likely focus on the continued performance of the clinic segment, the strategy to defend and grow NeuroStar system sales against fierce competition, and the long-term vision for a company that has fundamentally reshaped its role in the mental health ecosystem.